Tag Archives: Samsung Biologics

June, 2018

29 June
Biogen Expands Biosimilars Business by Exercising its Option to Increase Ownership in Samsung Bioepis

CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) — Biogen (Nasdaq:BIIB) announced today it has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics Co., Ltd and Biogen. Under the terms of the 2012 joint venture agreement, Biogen will pay Samsung …
Share

19 January
Biogen-Samsung’s Enbrel Biosimilar Wins European Approval

ZUG, Switzerland–(BUSINESS WIRE)–The joint venture between Biogen (NASDAQ:BIIB) and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI® , an etanercept biosimilar referencing Enbrel®i. BENEPALI has been granted marketing authorization in the European Union (EU) for the treatment of adults with moderate to severe rheumatoid arthritis …
Share

20 November
EU Endorses Biogen and Samsung Bioepis’ Biosimilar Version of Enbrel

ZUG, Switzerland–(BUSINESS WIRE)–Biogen (NASDAQ:BIIB) today announced further progress as part of its commitment to biosimilars. Samsung Bioepis, the joint venture between Samsung Biologics and Biogen, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorization …
Share